Allogene Therapeutics (ALLO) Deferred Taxes (2018 - 2019)
Allogene Therapeutics recorded quarterly Deferred Taxes of $33000.0 in Q3 2019, up 120.75% quarter-over-quarter from -$159000.0 in Q2 2019.
Allogene Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $33000.0 for Q3 2019.
- In Q3 2019, Deferred Taxes changed N/A year-over-year to $33000.0; the TTM figure through Sep 2020 stood at $33000.0 (down 99.92% YoY), while the FY2018 annual figure was $41.9 million, changed N/A from the prior year.
- Deferred Taxes came in at $33000.0 for Q3 2019 at Allogene Therapeutics, up from -$159000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $41.9 million in Q4 2018 to a low of -$159000.0 in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 33,000.00 |
| Jun 30, 2019 | -159,000.00 |
| Mar 31, 2019 | -50,000.00 |
| Dec 31, 2018 | 41.92 Mn |